Seattle Genetics and Agensys are also co-developing another ADC referred to as ASG-5ME, which is in phase I actually clinical trials for pancreatic and prostate cancer currently. Related StoriesRUCDR Infinite Biologics awarded $6 million grant from NINDSGenetics and race influence sufferers' response to anticancer drug treatmentsBrodalumab therapy achieves 100 percent reduction in psoriasis symptoms’ASG-22ME may be the second ADC we are co-developing under our collaboration with Agensys/Astellas, and the fifteenth ADC using Seattle Genetics’ technology in scientific advancement across both our internal pipeline and collaborator applications,’ stated Eric L.5 – Mesothelioma cancer scientific trials do not usually involve the use of a placebo A placebo can be an inactive ingredient or tablet found in some types of clinical trials to help make sure results are unbiased. A placebo is sometimes called a ‘sugar tablet.’ Over the years, doctors have observed that some people begin to feel better even if indeed they just think they’re getting treated. Although this effect tends to be brief, and does not really affect a cancer, it can make a fresh treatment seem to help. The possibility to getting a placebo will keep people from knowing if they’re getting the treatment being studied or not, making the results more likely to be valid. Placebos are rarely used alone in tumor study unless no known effective treatments exist. It’s definitely not ethical to possess someone have a placebo if an effective standard treatment has already been available especially regarding a grave disease like mesothelioma cancer tumor.